Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders under its existing prospectus.
The supplement states the registered shares consist of convertible-note conversions, consulting-share issuances and a warrant, and that the company will not receive proceeds from resales by the selling stockholders. The supplement also attaches an 8-K dated March 13, 2026 reporting that the company issued 3,277,099 shares pursuant to exchanges that cancelled convertible notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest, issued at an exchange price of $0.21 per share.
ParkerVision, Inc. files a prospectus supplement to register 17,189,660 shares of Common Stock for resale by selling stockholders under prior registration statements. The supplement incorporates the Company’s Form 8-K dated March 13, 2026 concerning exchange transactions.
Separately, the Company issued 3,277,099 shares of Common Stock on March 13, 2026, in exchange under Section 3(a)(9) for cancellation of convertible notes with an aggregate principal of $675,000 plus approximately $13,200 of accrued interest at an exchange price of $0.21 per share.
ParkerVision, Inc. registered 12,800,000 shares of Common Stock by prospectus supplement dated March 13, 2026.
The supplement states the 12,800,000 shares consist of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 to fund patent enforcement and working capital.
Separately, the company entered into exchange agreements dated March 13, 2026 to cancel convertible notes: the company issued 3,277,099 shares at an exchange price of $0.21 per share in exchange for cancellation of notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest.
ParkerVision, Inc. entered into exchange agreements with certain holders of its convertible promissory notes. The holders agreed to swap the notes’ outstanding principal and accrued interest for common stock at an exchange price of $0.21 per share under a Section 3(a)(9) registration exemption.
The company issued 3,277,099 shares of common stock to these holders in exchange for the cancellation of notes with an aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200. The exchanged notes were cancelled and are no longer outstanding, reducing this portion of ParkerVision’s debt.
ParkerVision reported an insider equity award to its leader. On January 22, 2026, Chief Executive Officer and director Jeffrey Parker received a grant of a performance-based nonqualified stock option covering 8,000,000 shares of ParkerVision common stock with an exercise price of $0.24 per share. The option vests based on specified performance conditions that are measured quarterly over a five-year performance period. Any portion of the option that has not vested by January 22, 2031 will be cancelled. After this grant, Parker is shown as directly holding 8,000,000 derivative securities related to this option.
ParkerVision Inc. Chief Financial Officer Cynthia L. French reported the grant of two nonqualified stock option awards. On January 22, 2026, she was awarded 500,000 nonqualified stock options with an exercise price of $0.24 per share, exercisable in four equal bi-annual installments beginning July 22, 2026. She also received 500,000 performance-based nonqualified stock options at an exercise price of $0.24 per share, which vest based on specified performance conditions measured quarterly over a five-year period. Any portion of this performance-based grant that does not vest by January 22, 2031 will be cancelled.
ParkerVision Inc. director Paul A. Rosenbaum received a stock option grant as part of his 2026 Board compensation. On January 22, 2026, he was awarded an option to purchase 370,000 shares of ParkerVision common stock at $0.24 per share, held directly. This option represents his beneficial ownership of 370,000 derivative securities after the transaction.
The option vests in two equal installments, with half vesting on July 22, 2026 and the remaining half on January 22, 2027, aligning the award with continued Board service over that period.
ParkerVision Inc. director Lewis H. Titterton Jr. reported an award of stock options as compensation for 2026 Board service. On January 22, 2026, he received an option to purchase 370,000 shares of common stock at an exercise price of $0.24 per share. Following this grant, he beneficially owns 370,000 derivative securities directly. The option vests in two equal installments on July 22, 2026 and January 22, 2027, aligning vesting with his Board service period.
ParkerVision Inc. reported a stock option award to director Robert Greene Sterne. On January 22, 2026, he received an option to purchase 370,000 shares of common stock at an exercise price of $0.24 per share, expiring January 22, 2031.
The option is compensation for 2026 Board service and vests in two equal installments on July 22, 2026 and January 22, 2027. After this grant, Sterne beneficially owns 370,000 derivative securities directly.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 9,387,500 shares of common stock. These shares include stock already issued under prior securities purchase agreements, shares issuable upon conversion of certain convertible notes at a fixed price of $0.16 per share, and shares issuable upon exercise of options granted as payment for services. The company will not receive proceeds from resales by the selling shareholders, but could receive up to $42,620 in gross proceeds if the service options are exercised for cash.
Separately, the compensation committee granted performance-based stock options for up to 8,000,000 shares to the CEO and 500,000 shares to the CFO, plus a time-based option for 500,000 shares to the CFO, all with a $0.24 exercise price. The performance options vest based on cumulative net cash from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The committee also approved a 2.5% cost-of-living increase to the CEO’s and CFO’s base salaries.